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Abstract
Host defence peptides (HDPs) are expressed throughout the animal and plant kingdoms. They have multifunctional roles in
the defence against infectious agents of mammals, possessing both bactericidal and immune-modulatory activities. We
have identified a novel family of molecules secreted by helminth parasites (helminth defence molecules; HDMs) that exhibit
similar structural and biochemical characteristics to the HDPs. Here, we have analyzed the functional activities of four HDMs
derived from Schistosoma mansoni and Fasciola hepatica and compared them to human, mouse, bovine and sheep HDPs.
Unlike the mammalian HDPs the helminth-derived HDMs show no antimicrobial activity and are non-cytotoxic to
mammalian cells (macrophages and red blood cells). However, both the mammalian- and helminth-derived peptides
suppress the activation of macrophages by microbial stimuli and alter the response of B cells to cytokine stimulation.
Therefore, we hypothesise that HDMs represent a novel family of HDPs that evolved to regulate the immune responses of
their mammalian hosts by retaining potent immune modulatory properties without causing deleterious cytotoxic effects.
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Introduction
Host defence peptides (HDPs) are found in all living organisms
and play a pivotal role as effector components of the innate
immune system [1,2]. They act as the first line of defence against
pathogenic assaults from bacteria, fungi, eukaryotic parasites and
viruses [3–5]. A range of HDPs with varied sequence lengths,
structures and activities have been characterized [6] and since
sequence identity between them is often very poor, their
classification is based largely on homologous secondary structures.
The two predominant HDP groups found in nature are the
cathelicidins, characterized by a-helical secondary structure, and
the defensins, which contain b-sheets stabilized by intra-molecular
disulfide bridges [7–9]. Despite the diversity in their sequences and
structures, HDPs are typically small amphipathic peptides (12–50
amino acids) with a net positive charge (+2 to +9) and consist of at
least 50% hydrophobic amino acids [10]. These biochemical
properties are central to the HDPs antimicrobial function by
allowing their interaction with, and disruption of, negatively
charged bacterial membranes [10].
The contribution of mammalian HDPs to the innate immune
response extends beyond direct bacterial killing. The elevated
expression of HDPs in response to damage (injury or infection) has
led to the suggestion that mammals utilize these peptides as
‘alarmins’ to activate the mobilization of a comprehensive immune
response [11]. Besides their antimicrobial activity, HDPs function
as potent immune regulators, selectively altering host gene
expression, inducing chemokine production, inhibiting bacterial-
or hyaluronan-induced pro-inflammatory cytokine production,
promoting wound healing and modulating T and B cell function
[reviewed in [12–14]. The net result of these activities is a balance
between pro- and anti-inflammatory immune responses which
prevents an exacerbated inflammatory response while concurrent-
ly stimulating the resolution of infection and repair of damaged
epithelia.
The immune response elicited by helminth (worm) parasites is
akin to the innate immune response to tissue injury and wound
healing [15,16]. Typically, this consists of a suppression of classical
pro-inflammatory responses and the induction of anti-inflamma-
tory regulatory Th2 type immune responses. While classical Th1-
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associated inflammatory mediators can provide protection from
helminths [17], there is a substantial cost in collateral damage to
host tissue [15,18]. In addition, due to their migration and feeding
activities, helminth parasites cause considerable local tissue
damage. Therefore, it has been proposed that on exposure to
helminths, the most beneficial outcome is to shut down a
destructive Th1-type response in favour of a Th2 response that
rapidly and effectively heals tissue [15,17,18]. Ultimately this
means that the parasite is tolerated by the host, remaining in situ
for many years and thus successfully completes its lifecycle.
Some advances have been made in identifying the signalling
molecules that initiate helminth-associated Th2 responses. Many
of these (such as IL-33 and Thymic stromal lymphopoietin
(TSLP)) are thought to be released by epithelial cells damaged by
migrating parasites [15,19]. However, a number of helminth-
derived products have also been shown to modulate the function of
innate immune cells and thus are potentially instrumental in the
initiation of Th2 immune responses [19,20]. We have previously
shown that a cysteine protease secreted by the trematode helminth
Fasciola hepatica prevented the induction of pro-inflammatory
macrophages and dendritic cells [21,22]. In addition, peroxir-
edoxin, also secreted by F. hepatica, promoted the development of
Th2 host immune responses [23,24]. Importantly, homologues of
these proteins are found in other medically-important trematode
parasites which we have suggested reveals a common mechanism
of immune-modulation employed by this class of pathogen.
As part of our on-going analysis of the secretome of F. hepatica
we recently discovered a novel 8 kDa protein. On analysis, this
protein shared structural and biochemical similarities to mamma-
lian cathelicidins and was therefore termed F. hepatica Helminth
Defence Molecule 1 (FhHDM-1) [25]. Like the human cathe-
licidin LL-37 precursor CAP-18, FhHDM-1 is proteolytically
processed (by a parasitic endopeptidase, cathepsin L1) to release a
34-residue C-terminal peptide previously named FhHDM-1 p2
[25]. This peptide adopts an amphipathic helix structure and, like
LL-37, can bind to Escherichia coli lipopolysaccharide (LPS) to
prevent its interaction with the toll-like receptor (TLR) 4/MD2/
CD14 complex on macrophages. Hence we proposed that F.
hepatica utilized FhHDM-1 as a molecular mimic of mammalian
cathelicidin-like HDPs as a means of controlling host innate
immune responses [25].
Phylogenetic analysis showed that FhHDM-1 is a member of a
family of HDMs conserved throughout several major animal and
human trematodes such as Schistosoma, Fasciola, Opisthorchis,
Clonorchis and Paragonimus species [25]. Importantly, all HDM
molecules in this family have preserved the C-terminal amphi-
pathic helix. Here, we have performed a comparative functional
study between several anti-microbial HDPs derived from well-
characterized mammalian cathelicidins and parasite-derived
peptides. For the helminth-derived peptides we selected
FhHDM-1p2 and two homologs derived from Schistosoma mansoni
which we term S. mansoni HDM-1 (SmHDM-1p146) and HDM-2
(SmHDM-2p58). In addition, we included a peptide derived from
a previously characterized secretory molecule of S. mansoni, termed
Sm16-p73 [26], which our phylogenetic studies suggest is a
divergent member of the HDM superfamily [25]. We show that, in
contrast to the mammalian HDPs (LL-37, CRAMP, BMAP-28
and SMAP-29), the trematode-derived HDMs are not cytotoxic or
bactericidal. However, like the mammalian HDPs, the trematode
HDMs suppress the activation of macrophages by microbial
stimuli and alter the isotype of immunoglobulin secreted by B cells.
We propose that HDMs represent a novel family of HDPs that
have undergone specific adaptation to retain potent immune
modulatory properties in the absence of deleterious cytotoxic
effects and are exploited by helminth pathogens to regulate the
immune responses of their mammalian hosts.
Methods
Synthetic mammalian and trematode peptides and their
biochemical properties
Four synthetic cathelicidin-derived peptides from diverse
mammalian species were used: SMAP-29 from sheep [27,28],
CRAMP from mice [29], LL-37 from human [30], and BMAP-28
from cattle [31]. The 34-residue C-terminal FhHDM-1 peptide,
termed FhHDM-1p2, has been previously described [25]. Sm16-
p73 peptide is 35 residues in length, corresponding to residues 73–
107 of the full-length protein S. mansoni Sm16 (GenBank accession
number: AAD26122.1). SmHDM-1p146 is 35 residues in length
and corresponds to residues 146–180 of the full length protein
(GenBank accession number XP_002580563.1). Finally,
SmHDM-2p58 is a 32 residue peptide that corresponds to residues
58–98 from the full length protein (GenBank accession number:
XP_002576627.1). All mammalian and trematode peptides were
synthesized by GenScript (NJ, USA) and supplied endotoxin-free.
The single letter code sequence of each peptide is shown in
Table 1.
The biochemical characteristics for each of the HDMs and
HDPs were calculated using tools available from the Antimicrobial
Peptide Database (http://aps.unmc.edu/AP/main.php) [32] and
are presented in Table 1. Predicted properties were total net
charge, Boman index, hydrophobic ratio and total hydrophobic
residues on the same hydrophobic surface of the alpha helix.
HDM sequence analysis
We have previously shown, using circular dichroism (CD)
spectroscopy, that FhHDM-1 has the propensity to adopt alpha-
helical structure in solution [25]. To assess whether HDMs from
Author Summary
In mammals, secreted host defence peptides (HDPs)
protect against a wide range of infectious pathogens.
They also perform a range of immune modulatory
functions which regulate the immune response to path-
ogens, ensuring that the protective inflammatory response
is not exacerbated and that post-infection repair mecha-
nisms are initiated. We identified a novel family of
molecules secreted by medically-important helminth
pathogens (termed helminth defence molecules; HDMs)
that exhibit striking structural and biochemical similarities
to the HDPs. To further investigate the extent of this
similarity, we have performed a comparative functional
study between several well characterized, anti-microbial,
mammalian HDPs and a series of parasite-derived pep-
tides. The parasite HDMs displayed immune modulatory
properties that were similar to their HDP homologs in
mammals, but possessed no antimicrobial or cytotoxic
activity. We propose that HDMs of these helminth
pathogens underwent specific adaptation, losing their
anti-microbial activity but retaining their ability to regulate
the immune responses of their mammalian hosts. This
absence of cytotoxicity and retention of immune-modula-
tory activity offers an opportunity to design novel
immunotherapeutics derived from the HDMs which could
be used to combat destructive inflammatory responses
associated with microbial infection and immune-related
disorders.
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the related trematode parasite S. mansoni also form alpha helices,
secondary structure prediction was performed using JPred 3 ([33];
http://www.compbio.dundee.ac.uk/www-jpred/). Specific re-
gions predicted to form alpha helices were then subjected to
helical wheel analysis using Heliquest ([34]; http://heliquest.ipmc.
cnrs.fr/cgi-bin/ComputParams.py) to identify those with distinct
hydrophobic faces; i.e. are amphipathic. The atomic structures of
the vertebrate HDPs LL-37 (PDB ID: 2K6O) and BMAP-28 (PDB
ID: 2KET) were visualised for comparison using the PyMOL
Molecular Graphics System, Version 1.5.0.4 Schro¨dinger, LLC.
(http://pymol.org/).
Bacterial lipopolysaccharide binding assay
Lipopolysaccharide (LPS) binding was performed using a
quantitative chromogenic Limulus amoebocyte assay (Chromo-
LAL assay; Associates of Cape Cod Incorporated) following
manufacturer’s recommendations. Assays were performed in flat-
bottom endotoxin- and glucan-free 96-well plates (Associates of
Cape Cod Incorporated). Stock solutions of each peptide were
prepared in endotoxin-free water (80 mg/ml) and diluted to a
final concentration of 250 pmol/ml. In the first step, 25 ml of
peptide solution was mixed with 25 ml of a solution containing 1
endotoxin U/ml of Escherichia coli O113:H10 LPS and incubated
for 30 min at 37uC to allow peptide and LPS binding to occur.
The second step involved the addition of 50 ml of the chromo-
LAL reagent. The liberation of r-nitroaniline was monitored
every 60 sec at 405 nm with a Synergy H1 hybrid reader (Biotek)
while the temperature was maintained at 37uC. Each peptide
concentration was also incubated with 25 ml of LPS-free water as
a control to determine if the peptide itself could activate the
Chromo-LAL assay. The experiment was conducted twice in
triplicate. Standard deviation was calculated from these six
replicates.
Antimicrobial assays
The minimal inhibitory concentration (MIC) of each peptide
against various bacteria was determined using a standardized
dilution method according to NCSLA guidelines [35]. Overnight
colonies of E. coli, Pseudomonas aeruginosa, Salmonella typhimurium,
Staphylococcus epidermis and Staphylococcus aureus, were suspended to a
turbidity of 0.5 OD units and further diluted in Mueller-Hinton
broth (MHB). For determination of MIC, peptides were prepared
in an acetic acid/BSA solution and used in graded concentrations
(0, 1, 2, 4, 8, 16, 32, 64, and 128 mg/ml) from a stock solution. Ten
microliters of each concentration was added to each corresponding
well of a 96-well polypropylene microtiter plate and 16105
bacteria in the volume of 90 mL. The plate was incubated at 37uC
for 16 h and then read at 600 nm with a Synergy H1 hybrid
reader (Biotek).
Haemolytic activity
The peptide’s haemolytic activities were determined using
human red blood cells (RBCs; Research Blood Components,
LLC) in 96-well polypropylene microtiter plates. One hundred
ml of 0.5% RBC suspension was added to an equal volume of a
peptide (8–256 mg/ml). After 1 h at 37uC, plates were
centrifuged at 14206g for 5 min and the optical density of
the supernatant was measured at 414 nm with a Synergy H1
hybrid reader (Biotek). Values for 0% and 100% lysis were
obtained by adding PBS or Triton X-100 (1%; final concen-
tration) to RBCs, respectively. All assays were performed in
triplicate and the values of percent lysis were within a 1%
standard deviation range.
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Measurement of cellular pore formation
RAW 264.7 murine macrophages (56105 cells) were incubated
in the presence of the fluorescent dye TO-PRO (Life Technolo-
gies) for 60 sec. After the peptides (50 mM) were added to the
culture media the uptake of dye was measured for 360 sec by flow
cytometry.
Cytotoxicity assay
RAW 264.7 murine macrophages (16106cells) were incubated
with a range of concentrations (2.5–50 mM) of peptides for 1 h at
37uC. The culture supernatants were collected and assayed for
LDH activity with the CytoTox LDH release kit (Promega)
according to the manufacturer’s instructions. The amount of LDH
released is expressed as a percentage of the total amount of LDH
released from cells treated with lysis buffer (regarded as 100%
cytotoxicity).
Effect of peptides on Cryptosporidium spp. sporozoite
viability
Oocysts of the Iowa C. parvum isolate [36] were propagated in
experimentally infected newborn Cryptosporidium–free Holstein bull
calves to obtain parasite material for study as previously described
[37,38]. Oocysts were isolated by sucrose density gradient
centrifugation, stored in 2.5% (W/V) potassium dichromate
(4uC) and used within 6 weeks of isolation [39]. Oocysts of the
TU502 C. hominis isolate [40,41] were propagated in gnotobiotic
piglets and isolated from feces at Tufts University [42] and used
within 4 weeks of isolation. Prior to excystation, oocysts were
treated with hypochlorite [37]. In vitro excystation (37uC, 0.15%
[W/V] taurocholate, 2 h) of oocysts used for all experiments was
$90%. Sporozoites were isolated from excysted oocyst prepara-
tions by passage through a polycarbonate filter (2.0 mm pore size;
Poretics, Livermore, California) and used immediately.
Sporozoite viability after incubation with peptides was assessed
using fluorescein diacetate (FDA) and propidium iodide (PI) with
modification [43]. In brief, freshly excysted sporozoites were
incubated (15 min, 37uC) in minimal essential medium (MEM)
containing individual peptides (2.5, 0.25, 0.025 mM) or in MEM
alone (n = 3). Peptide concentrations were selected based largely
on studies by our group and others evaluating the effects of various
antimicrobial peptides on C. parvum viability [44–47]. Heat-killed
(20 sec, 100uC) sporozoites were used as a control. FDA (8 mg/ml
final concentration) and PI (3 mg/ml final concentration) were
then added to the sporozoite preparations and incubated further
(5 min, 21uC). A minimum of 100 sporozoites were then examined
by epifluorescence microscopy for each preparation, and the
percent viability was determined. Percent reduction of viability
was calculated as ([MEM-treated sporozoite viability2peptide-
treated sporozoite viability]4MEM treated sporozoite viabili-
ty)6100. The mean values for test and control preparations were
examined for significant differences using Student’s t-test.
Purification and activation of bone marrow-derived
murine macrophages
CD11b+F4/80+ macrophages were derived (99% purity) from
the bone marrow of BALB/c mice by culturing with M-CSF
(ebioscience) over 6 days and then seeded in RPMI (with 10% FBS
v/v) at a concentration of 16105 cells/ml. These cells were
incubated with peptides (0.5 mM–5 mM) for 1 h at 37uC, in the
absence of mCSF. Following two washes with ice-cold PBS, cells
were incubated with a combination of E. coli LPS (10 ng/ml;
Sigma) and IFNc (10 ng/ml; BD Pharmingen) overnight. Super-
natants were then collected and the amount of TNF measured by
ELISA according to the manufacturer’s instructions (BD Pharmin-
gen).
Purification and activation of murine B cells
B cells were isolated from the spleens of BALB/c mice by
negative selection using a B cell isolation kit containing biotin-
conjugated mAbs to CD43, CD4, and Ter-119 (Miltenyi Biotec)
and then seeded at a concentration of 16106 cells/ml in RPMI
(with 10% FBS v/v). The cells were treated with a range of
concentrations of peptides (0.5 mM–5 mM) for 1 h at 37uC. After
washing, the B cells were incubated with a combination of either
E. coli LPS (10 mg/ml; Sigma) and IL-4 (10 ng/ml; BD Pharmin-
gen) or E. coli LPS (10 mg/ml) and IFNc (200 ng/ml; BD
Pharmingen) for six days. Supernatants were then collected and
the amount of IgG1 or IgG2a measured by ELISA (Sigma).
Statistical analyses
Statistical comparisons were performed with Prism 4.0 Software
(Graph- Pad), using two-tailed Student’s t test for comparisons of
two data sets, and ANOVA for multiple comparisons. Statistically
significant differences were determined by a p value of *,0.05,
**,0.01, ***,0.001.
Results
HDMs, like mammalian HDPs, are cationic, have a high
percentage of hydrophobic amino acids and form
amphipathic structures
The biochemical properties for each of the HDMs and HDPs
are presented in Table 1. The cathelicidins are known to be highly
cationic peptides. Except for the FhHDM-1p2 peptide, which has
a net charge of 0, all the peptides in the present study have a net
positive charge (+3 to +9) with a percentage of hydrophobic
residues ranging from 34 to 44. The Boman index is an estimated
potential of peptides to bind to other proteins. For this index, a low
value (#1) suggests that a peptide has more antibacterial activity,
whereas values ranging from 2.5–3.0 indicate that a peptide is
multifunctional with hormone-like activities [48]. While BMAP-28
has a low Boman index (0.81) which correlates to its high
antimicrobial activity, the Boman indices for the other peptides
range from 1.34–3.11. Overall, there is no striking difference
between the biochemical properties of HDMs and HDPs.
The atomic structures of the vertebrate HDPs LL-37, CRAMP,
BMAP-28 and SMAP-29 have been previously solved and
determined that each form an amphipathic helix [31,49–51]
(figure 1). The structures of LL-37 and BMAP-28 are shown in
figure 1A as representative for this group of peptides. Secondary
structure prediction of the parasite-derived peptides FhHDM-1p2,
SmHDM-1p146, SmHDM-2p58 and Sm16-p73 revealed that all
possessed regions likely to form alpha helices. Furthermore, helical
wheel analysis showed that each molecule contained an alpha
helix (32–35 amino acids) toward the C-terminal that was
distinctly amphipathic. The number of residues forming the
hydrophobic face of the parasite molecules ranged from 6–9
(figure 1B). Thus, like their vertebrate HDP counterparts, the
secreted helminth parasite molecules also form distinct amphi-
pathic helices.
Helminth defence molecules variably bind LPS
Mammalian HDPs have the ability to bind to and thus
neutralize the bacterial endotoxin LPS [52–57]. The capacity of
different mammalian and helminth peptides to bind LPS from E.
coli O113:H10 was compared using the chromogenic Limulus
Helminth Cathelicidins Adapted for Immune Modulation
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amoebocyte assay (Chromo-LAL). The Limulus amoebocyte lysate
contains enzymes that are activated in a cascade of reactions in the
presence of LPS [58–60]. The final enzyme in the series splits the
chromophore, r-nitroaniline (rNA), from the chromogenic
substrate, generating a yellow color. The amount of rNA released
is proportional to the amount of free LPS present in the system.
Consistent with that published in the literature, mammalian
HDP LL-37, BMAP-28, SMAP-29 and CRAMP inhibited the
activation of the Chromo-LAL assay at a concentration of
250 pmol/ml, indicating that they interact with LPS and thus
prevent the activation of the enzymatic cascade [52,53,55,61]
(figure 2). BMAP-28 was the most potent, preventing the
activation of the enzyme cascade with a Vmax of 3.1 and
SMAP-29 was less effective with a Vmax of 26.5. Of the helminth-
derived HDPs, both Sm16-p73 and SmHDM-1p146 displayed
no LPS-binding capacity with a Vmax of 40.4 and 31.1,
respectively, which were above the control reaction with no
peptide (Vmax of 28.5). By contrast, the helminth peptide
SmHDM-2p58 was the second best inhibitor of the series with
a Vmax of 12.5, just after BMAP-28.
Figure 1. Mammalian and helminth cathelicidin-like peptides share homologous secondary structure. (A) Most HDPs, including those
used in the present study, form amphipathic helices. Here, the atomic structures of LL-37 (PDB ID: 2K6O) and BMAP-28 (PDB ID: 2KET) are shown as
green ribbon with the residues comprising the hydrophobic face of the molecules coloured red. Structures were generated using Pymol (http://www.
pymol.org). (B) Helical wheel analysis shows that peptides derived from FhHDM-1p2 (residues 14–34), Sm16-p73, SmHDM-1p146 and SmHDM-2p58
(residues 9–26 for each) also form distinct amphipathic structures.
doi:10.1371/journal.pntd.0002307.g001
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We found that FhHDM-1p2 was capable of directly activating
the Chromo-LAL assay itself (data not shown) and, therefore, its
binding capacity could not be evaluated using this test. However,
using a plate-binding assay we have previously demonstrated that
FhHDM-1p2 does indeed bind to LPS [25].
Helminth defence molecules do not possess
antimicrobial or anti-protozoan activity
The bactericidal properties of mammalian HDPs are mediated
by direct antimicrobial activities, and are therefore easily evaluated
as the minimal concentration capable of inhibiting visible
Figure 2. Mammalian and helminth cathelicidin-like peptides display varied LPS binding capacity. 25 ml of peptide (250 pmol/ml) was
incubated with 25 ml of LPS from E. coli O113:H10 (1 EU/ml) for 30 min at 37uC to allow the interaction between both molecules. Chromo-LAL reagent
was then added and the liberation of r-nitroaniline was monitored every 60 sec at 405 nm. The top panel is a representative of the curves obtained
for each peptide. The data presented in the Table is the mean of three replicates from two separate experiments. The extent of binding of peptide to
LPS prior to adding the mixture to the Chromo-LAL is reflected in the reduced rate of cleavage of the substrates and a corresponding inability of the
reaction to reach maximum velocity (Vmax).
doi:10.1371/journal.pntd.0002307.g002
Helminth Cathelicidins Adapted for Immune Modulation
PLOS Neglected Tropical Diseases | www.plosntds.org 6 July 2013 | Volume 7 | Issue 7 | e2307
microbial growth (MIC) against a panel of bacterial species.
Consistent with previous reports [28,31,62,63], we found that
SMAP-29 and BMAP-28 were effective against a broad group of
gram-negative bacteria, including E. coli, P. aeruginosa, and S.
typhimurium and two gram-positive bacteria, S. aureus and S.
epidermis, with MIC values of,0.25–8 mg/ml (Table 2). LL-37 and
its mouse counterpart, CRAMP, showed bactericidal activity
against gram-negative bacteria with MIC ranging from 2 to 8 mg/
ml, but were ineffective against the gram-positive bacteria tested
(MIC,128 mg/ml). The inactivity of LL-37 against S. aureus and S.
epidermis is consistent with other studies [64]. However, the anti-
microbial effect of LL-37 on Staphylococcus could be strain
dependent as several studies have reported an effect of this peptide
on both S epidermis [65] and S. aureus [66,67]. Despite structural
similarities with the mammalian peptides tested, none of the
HDMs demonstrated bactericidal activity against any species of
bacteria at the concentrations tested (,0.25 to 128 mg/ml).
We have recently shown that cationic peptides, including the
cathelicidin LL-37, are highly parasiticidal against the apicom-
plexan parasite C. parvum in vitro [47]. Using the same methodology,
we compared the anti-parasite activity of the mammalian HDPs to
that of the four helminth-derived peptides. In keeping with our
previous data [35], LL-37 exhibited parasiticidal activity at a
concentration of 2.5 mM against C. parvum and the related species C.
hominis (figure 3). The other mammalian cathelicidins showed
greater parasiticidal activity, reducing the viability of protozoans at
lower concentrations of 0.025 and 0.25 mM. Of particular note,
BMAP-28 demonstrated the highest potency against both species of
protozoan at 2.5 mM (P,0.01). In stark contrast to these results, was
the relative absence of parasiticidal activity of the helminth-derived
peptides, even at the highest concentration of 2.5 mM.
Helminth defence molecules are not cytotoxic to
mammalian cells
The predominant mechanism of HDP bactericidal activity is the
formation of pores in the membrane lipid bilayer, destroying its
integrity and causing cell death [68]. However, this effect is not
specific to bacterial cells and HDPs have also been shown to be
cytolytic to eukaryotic cells, particularly at high concentrations
[69]. TO-PRO is a membrane impermeant dye and therefore its
detection within cells is indicative of pore formation. Using this
dye, we demonstrated that, as expected, all mammalian peptides
at a concentration of 50 mM (equivalent to the highest concen-
tration tested in the bactericidal assays) induced the formation of
pores in a murine macrophage cell line (figure 4). However, at the
same concentration none of the helminth peptides exhibited this
effect.
To more completely assess the cytotoxicity of the peptides, we
first examined their haemolytic activity against human RBCs at
various concentrations (8–256 mg/ml). After one hour of co-
incubation, all of the mammalian peptides induced concentration
dependent hemolysis (Table 3). BMAP-28 was the most potent of
all the peptides, with 50% of RBCs lysed at the lowest
concentration of peptide tested (8 mg/ml) and 70% at the highest
concentration of 256 mg/ml. In comparison, at this highest
concentration, the other mammalian peptides were much less
cytotoxic, lysing only 14.5–29.3% of RBCs. Notably, under the
same experimental conditions, the S. mansoni-derived peptides did
not lyse the cells at any concentration tested. The F. hepatica-
derived FhHDM-1p2 showed some low-level cytolytic activity,
with 11.4% of cells lysed at the highest concentration of 256 mg/
ml.
Lactate Dehydrogenase (LDH) is a soluble cytosolic enzyme
that is released into culture media following loss of membrane
integrity resulting from either apoptosis or necrosis. Therefore
LDH release is an indicator of cell membrane integrity and acts as
a measure to assess cytotoxicity. Consistent with the demonstration
of hemolysis, higher concentrations (.10 mM) of mammalian
peptides also resulted in the death of murine macrophages, with
the highest concentration tested (50 mM) resulting in 100%
cytotoxicity, compared to the effect of a lysis buffer (figure 5). By
contrast, none of the helminth peptides induced cell death at any
concentration tested. This lack of LDH detection was not due to
enzyme inhibition by the helminth peptides; when the peptides
were added directly to culture supernatant from lysed cells the
LDH activity was unchanged. Consistent with these data, the cells
treated with helminth peptides (10–50 mM) looked morphologi-
cally normal by light microscopy (data not shown).
Both mammalian- and helminth-derived peptides
suppress secretion of the inflammatory cytokine TNF
from macrophages
Activation of macrophages by microbial stimuli is central to the
induction of innate immune responses. IFNc is one of the key
Table 2. Antibacterial activity of mammalian- and helminth-derived peptides against gram-positive and gram-negative bacteria
assessed by micro broth assay.
MIC1 in mg/ml
Gram-negative Gram-positive
Escherichia coli Pseudomonas aeruginosa Salmonella typhimurium Staphylococcus epidermis Staphylococcus aureus
FhHDM-1p2 .128 .128 .128 .128 .128
Sm16-p73 .128 .128 .128 .128 .128
SmHDM-1p146 .128 .128 .128 .128 .128
SmHDM-2p58 .128 .128 .128 .128 .128
LL-37 4 8 2 .128 .128
CRAMP 2 4 4 .128 .128
SMAP-29 ,0.25 ,0.25 ,0.25 ,0.25 2
BMAP-28 1 4 4 4 8
1MIC: minimum inhibitory concentration determined by a conventional microbroth-based assay in Mueller Hinton medium supplemented with acetic acid/BSA [57].
doi:10.1371/journal.pntd.0002307.t002
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cytokines in the innate immune response to intracellular patho-
gens, and augments cellular responses to TLR ligands such as
bacterial LPS [70,71]. To prevent excessive inflammation
potentially leading to sepsis, HDPs have been shown to inhibit
the response of macrophages to these inflammatory mediators
using mechanisms that are independent of direct binding to LPS
[72]. Significantly, macrophages isolated from animals and
humans infected with helminth parasites are also hyporesponsive
to stimulation with LPS and IFNc [73,74]. Therefore, here we
investigated whether helminth-derived peptides, like mammalian
HDPs, could suppress the activation of inflammatory macrophag-
es. At concentrations below cytotoxic levels (,5 mM), all
mammalian peptides significantly inhibited TNF production in
response to the combined stimulation with LPS and IFNc
(figure 6). Titration of the peptide concentration showed that
even at concentrations as low as 0.5 mM, the inhibitory activity
was preserved. In contrast, at the lowest concentration tested, the
helminth-derived peptides had no effect on the activation of
macrophages. However, as the concentration was increased, the
helminth peptides significantly suppressed the inflammatory
response of macrophages and in most cases more effectively than
the mammalian peptides (figure 6). It is worth noting that the
helminth-derived peptides could be tested at concentrations up to
50 mM as they are non-toxic to cells, whereas due to their
cytotoxicity the HDPs were not tested at concentrations above
10 mM (figures 4,5). At these higher concentrations (10, 25 and
50 mM) the helminth-derived peptides significantly reduced the
production of TNF from activated macrophages in a concentra-
tion dependent manner (data not shown).
Both mammalian- and helminth-derived peptides alter
the secretion of immunoglobulin from activated B cells
In addition to directly inhibiting inflammatory innate
immune responses, there is evidence that mammalian HDPs
have an additional role in regulating the magnitude of the
adaptive antibody responses. For example, it has been shown
that CRAMP functions to positively regulate the level of IgG1
produced by B cells [75], and LL-37 reportedly decreased the
production of IgG2a from mouse splenic B cells activated with
LPS and IFNc [76]. Consistent with these reports, our analyses
showed that with the exception of BMAP-28, all the
mammalian HDPs significantly increased the production of
IgG1 in response to a Th2 biased environment (LPS and IL-4)
Figure 3. Mammalian, but not helminth, peptides reduce Cryptosporidium spp. sporozoite viability. The viability of C. parvum (A) and C.
hominis (B) sporozoites was assessed after incubation with peptides or in medium alone (untreated). Following the addition of FDA and PI, the
percent viability for each preparation was determined by epifluorescence. The data shown are means 6 SD.
doi:10.1371/journal.pntd.0002307.g003
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(figure 7A). The apparent reduction in IgG1 production
recorded for the higher concentration of BMAP-28, likely
reflects some level of cell death rather than a reduction in
antibody production. Due to this cytotoxicity the HDPs were
not tested at concentrations above 5 mM. While there was
greater variability between the HDMs, peptides from F. hepatica
and S. mansoni significantly increased the production of IgG1 in
response to LPS and IL-4 even at low concentrations.
Conversely, mammalian peptides reduced the production of
IgG2a in a Th1 (LPS and IFNc) biased environment (figure 7B).
For the helminth peptides, only concentrations above 5 mM had
the same effect on B cells, significantly (p,0.001) inhibiting IgG2a
secretion (data not shown), suggesting a lower potency than
mammalian-derived peptides.
Discussion
Parasitic helminths secrete molecules that modulate host
immune responses to establish an environment that facilitates
their survival and a prolonged reproductive phase [20,77,78]. Co-
evolution of helminths with their hosts means that these parasites
are well adapted to the host’s immune system, making use of
endogenous regulation mechanisms to manipulate the immune
response to their benefit. In this study, we compared the biological
activities of a series of helminth-derived cathelicidin-like peptides
to that of their mammalian homologues and suggest how their
production by helminths can facilitate a successful parasitic life
cycle.
In vitro, most mammalian HDPs are effective antimicrobial
agents against a range of organisms including gram-negative and
gram-positive bacteria, protozoa, viruses and fungi [10,79,80]. In
general, the expression of HDPs is increased at the onset of an
infection and therefore the anti-pathogenic activity was thought to
be one of the most important immediate responses that the
mammalian host evolved to deal with invading pathogens. It has
been proposed that the specificity of HDPs for particular microbes
is subjected to significant variation and is particularly influenced
by the types of microbial biotas to which each HDP species is
exposed [81]. Consistent with this theory, we showed some
variation in the anti-microbial capabilities of the mammalian
HDPs examined. While sheep and bovine derived peptides were
effective against a broad range of both gram-positive and gram-
Figure 4. Mammalian, but not helminth, peptides induce the formation of pores in macrophages. RAW macrophages were incubated in
the presence of TO-PRO. After 60 sec, 50 mM of mammalian (left panel) or helminth (right panel) peptides was added to the medium. The uptake of
fluorescent dye was measured over a period of 360 sec.
doi:10.1371/journal.pntd.0002307.g004
Table 3. Hemolytic activity of mammalian- and helminth-derived peptides.
Peptide Hemolytic activity in % at peptide concentrations (mg/ml)
8 16 32 64 128 256
FhHDM-1p2 0 0 1.8 2.6 5.4 11.4
Sm16-p73 0 0 0 0 0 0
SmHDM-1p146 0 0 0 0 0 0
SmHDM-2p58 0 0 0 0 0 0
LL-37 0 1.7 4.1 10.4 20 20
CRAMP 0 2.6 5.8 9.1 20.1 29.3
SMAP-29 0 0 0 2.6 6.7 14.5
BMAP-28 50.2 60.4 48.8 49.5 52.9 70.23
doi:10.1371/journal.pntd.0002307.t003
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negative bacteria, the mouse and human HDPs were largely
ineffective against the gram-positive species tested. However, we
found that none of the helminth-derived peptides displayed gram
positive or negative bactericidal activity, even at the highest
concentration tested, implying that their specialised function is not
anti-microbial. However, we cannot exclude the possibility of the
peptides having anti-microbial activity on other, untested patho-
genic bacteria.
Despite lacking bactericidal activity, we showed previously that
FhHDM1-p2, like the mammalian peptides, interacts with LPS,
thus effectively neutralising the ability of infecting bacteria to
induce an inflammatory response [25]. We suggested that this may
be a mechanism used by the parasite to prevent excessive
activation of innate cells in response to the translocation of
microbes into circulation occurring as a result of damage to the
skin and/or gut epithelium during migration of the parasite [25].
As the two major factors mediating interaction between LPS and
HDPs are hydrophobicity and cationicity [82], inspection of the
sequence of the other HDMs would predict a universal ability to
bind to LPS. However, while SmHDM-1p146 appeared to bind
LPS as efficiently as the mammalian peptides, neither SmHDM-
2p58 or Sm16-p73 were particularly potent, indicating that the
neutralization of LPS may not be a common function of the
helminth-derived peptides.
A number of studies have demonstrated the ability of amphibian
and mammalian HDPs to kill protozoan parasites in vitro [83,84].
For example, BMAP-28 possesses potent activity against the agent
of human leishmaniasis, Leishmania major [83], and we have shown
that LL-37 can reduce the viability and infectivity of sporozoites of
C. parvum, an intestinal infection of humans and agricultural
animals [47]. In the present study we confirm the activity of LL-37
against C. parvum and the related parasite C. hominis and show that
the other mammalian cathelicidins tested also have anti-protozoan
activity; BMAP-28 exhibited the most potent in vitro activity. By
Figure 5. Mammalian, but not helminth, peptides induce the release of LDH frommacrophages. RAWmacrophages were incubated with
peptides for 1 h at 37uC. The release of LDH by cells was measured and expressed as the percentage of LDH released after treatment of cells with lysis
buffer (regarded as 100%). Data shown are the means 6 SEM of triplicate samples and representative of three independent experiments.
doi:10.1371/journal.pntd.0002307.g005
Figure 6. Both mammalian and helminth peptides suppress secretion of the inflammatory cytokine TNF from macrophages. Primary
murine bone marrow derived macrophages were treated with peptides for 1 h, washed then subsequently stimulated with a combination of E. coli
LPS (10 ng/ml) and IFNc (10 ng/ml) for 16 h. The amount of TNF (pg/ml) secreted into the culture media was measured by ELISA. The data shown are
means 6 SEM of triplicate samples and are representative of three independent experiments.
doi:10.1371/journal.pntd.0002307.g006
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contrast, and consistent with their lack of antibacterial activity, the
helminth-derived HDMs did not kill either parasite in vitro.
Clearly, the particular physico-chemical properties of HDMs do
not confer an ability to penetrate and disrupt the surface
membrane of these parasitic organisms.
Although widely defined as antimicrobial, in fact, at the
concentrations normally found at human mucosal surfaces and
in physiological salt conditions, the mammalian cathelicidin-like
peptides do not display bactericidal activity. However, at these
same concentrations and under the same conditions, the peptides
exhibit a variety of immune modulatory functions [12,85]. This
has led to the suggestion that the cathelicidins are principally
immune modulators rather than antimicrobials, and like the
mammalian defensins, have traded their bactericidal capacities to
acquire the ability to broadly regulate the immune response
[12,86]. The mammalian cathelicidins have a diverse effect on the
cellular immune response, but in particular, the peptides have a
crucial role in regulating TLR-dependent innate inflammatory
responses. This means that they function to maintain homeostasis
in response to natural shedding of microflora-TLR agonists as well
as controlling the systemic inflammatory response to infection or
tissue damage [12,86,87]. We have shown here that the helminth-
derived cathelicidin-like peptides also regulated the innate immune
response to TLR stimulation by inhibiting TNF release from
macrophages stimulated with bacterial LPS. While the helminth
HDMs were not as effective as their mammalian homologues at
the lowest concentration tested, they were correspondingly more
potent as their concentration was increased towards quantities that
are likely secreted during infection. It is probable that the function
of these secreted HDMs is similar to the predicted role for the
mammalian HDPs, i.e. prevention of an excessive inflammatory
response, which acts to prevent the expulsion of the worm and to
protect the host from exacerbated tissue damage.
The role of HDPs in regulating the adaptive immune response
has been less extensively studied. Recent studies have shown that
LL-37 decreased the production of IgG2a from murine B cells
stimulated with LPS and IFNc [76], and that CRAMP increased
the amount of IgG1 in response to IL-4 [75]. These results are
consistent with the suggestion that HDPs are engaged in the
process of infection resolution and wound healing, as autoreactive
IgG1 antibody production is central to tissue repair processes [88],
while IgG2a are associated with IFNc/Th1-mediated inflamma-
Figure 7. Both mammalian and helminth peptides alter the secretion of immunoglobulin from activated B cells. Murine splenic B cells
were treated with a range of concentrations of peptides for 1 h at 37uC, washed and then incubated with a combination of either (A) E. coli LPS
(10 mg/ml) and IL-4 (10 ng/ml) or (B) E. coli LPS (10 mg/ml) and IFNc (200 ng/ml) for six days. Levels of IgG1 (A) and IgG2a (B) in cell supernatants were
measured by ELISA. The data shown are from triplicate samples, corresponds to the means 6 SEM, and are representative of two independent
experiments.
doi:10.1371/journal.pntd.0002307.g007
Helminth Cathelicidins Adapted for Immune Modulation
PLOS Neglected Tropical Diseases | www.plosntds.org 11 July 2013 | Volume 7 | Issue 7 | e2307
tory responses. Consistent with these reports, the helminth-derived
peptides performed in a similar manner to their mammalian
counterparts, successfully enhancing the production of IgG1. At
high concentrations, the helminth-derived peptides were far more
effective than mammalian HDMs at suppressing the release of
IgG2a in response to IFNc, supporting their role as potent anti-
inflammatory agents.
Due to their immune modulatory activities, there is considerable
interest in developing HDPs as therapeutics such as anti-
inflammatory agents, adjuvants and wound healing agents. The
therapeutic potential of HDPs has been demonstrated and a
number of peptides are being developed as anti-inflammatory
agents [89]. However, the clinical use of these peptides as
injectable therapeutics has been hampered by indications of toxic
side-effects on mammalian cells and their ability to lyse eukaryotic
cells [90,91]. This had led to intense research into understanding
how HDPs function in terms of their physico-chemical properties.
Among the factors that appear to influence specificity between
their activity against prokaryotic and eukaryotic cells are the
ability to form an amphipathic a-helical structure, hydrophobicity,
overall charge distribution, and minimal peptide length [92]. At
first sight, the biochemical characteristics of the helminth-derived
HDMs would predict an inherent cytotoxic activity: they form
amphipathic helices (figure 1), they have a comparable proportion
of hydrophobic amino acids to mammalian HDPs and most of
them are cationic (Table 1). However, based on the assays
employed in this study, we found no correlation between the level
of hydrophobicity and cytotoxic activity.
The majority of mammalian HDPs have an overall net charge
ranging from +4 to +6.37 [93], implying an optimal range for
biological activity. HDPs with a net positive charge of ,+4 are
found to be inactive, whereas increasing the net charge from +4 to
+8 confers antimicrobial activity and some haemolytic activity
[79]. Three of the HDMs used in this study, FhHDM-1p2,
SmHDM-1p146 and SmHDM-2p58, all had a net charge ,+4
which is consistent with a non-bactericidal, non-haemolytic
peptide. However, despite possessing a net charge of +5, Sm16-
p73 displayed neither antimicrobial nor cytotoxic activities.
Recent studies have proposed that rather than a simple correlation
between net charge and haemolysis it is the localisation of the
positively charged amino acids within the peptide that also dictates
membrane interaction and selectivity. By increasing the charge of
an amphipathic HDP analog from +8 to +9, by the addition of one
positive charge on the polar face, the haemolytic activity of the
peptide was enhanced 32-fold [79]. Using this parameter, we
calculated that Sm16 has four positively charged amino acids on
its polar face compared to six for LL-37, CRAMP and BMAP-28
and seven for SMAP-29, which may provide some clue as to the
difference in cytotoxicity between these peptides. Likewise, all the
helminth HDMs used in this study have less positive charges on
their polar face compared to LL-37, which was the least cytotoxic
of all the mammalian peptides examined in this study.
It is generally accepted that the cytoplasmic membrane is the
main target of many mammalian HDPs, whereby peptide
accumulation in the membrane causes increased permeability
and a loss of barrier function, resulting in the leakage of
cytoplasmic components and cell death [94]. However, the
cytotoxic concentrations of HDPs are higher than the concen-
trations required for the destruction of microbes, which, some
authors suggest, reveals a cell-selective killing mechanism
[85,94]. The physiological concentration of HDPs at mucosal
sites is typically less than 2 mg/ml [12,80], well below the
concentration that is cytotoxic to mammalian cells in vitro. We
have found that helminth HDMs are abundant molecules within
the secretions of helminth parasites, which during a multi-
parasite infection would likely be at relatively high concentra-
tions in circulation. Therefore, it is essential for the success of
the parasite that these peptides do not possess cytotoxic activity,
whilst at the same time retain the beneficial immune modulatory
properties. The complete absence of antimicrobial activity by
helminth-derived peptides is likely linked to this need to prevent
host cell death during infection.
The extraordinary capacity of helminths to regulate the
immune response is central to their longevity in the mammalian
host and thus underpins their success as parasitic organisms
[77,78]. Therefore, it is perhaps unsurprising that helminth
secretory products contain homologues of components of the host
immune system that target the same mammalian pathways. In
addition to the HDMs identified here, helminth parasites express
highly conserved cytokine gene families that, like their mammalian
counterparts, ligate specific receptors on immune cells. Brugia
malayi and Ancylostoma ceylanicum express homologues of the
mammalian cytokine macrophage migration inhibitory factor
(MIF) [95], and in a Th2 environment, such as that activated by
helminth infection, Brugia MIF synergises with IL-4 to induce the
development of regulatory M2 macrophages [96]. Helminths also
express members of the Tumour Growth Factor-(TGF)b and
TGF-b receptor superfamilies [97–99], and similar to the
mammalian cytokine, Heligmosomoides polygyrus TGF-b homologue
has been shown to directly induce the differentiation of regulatory
T cells, demonstrating a key role in parasite immune regulation
[100].
The cysteine protease inhibitors, cystatins, are an ancient
and conserved family of peptides in the animal and plant
kingdoms [101]. The cystatins of parasitic worms differ
substantially from those produced by free-living nematodes
with regard to their immune modulatory properties [102]. In
particular, the acquisition of an asparaginyl endopeptidase site,
similar to that of vertebrate cystatin C, confers an ability to
reduce the activation of host T cell responses by directly
inhibiting the presentation of antigen by dendritic cells
[103,104], suggesting a specific adaption to regulate host
immune responses [102,105]. Similar to the cystatins, HDPs
are conserved in all organisms, including plants, animals and
humans [106]. However, we show here that while the
helminth-derived HDMs are effective immune modulators,
they display no bactericidal activity. These observations would
suggest that like the cystatins, HDMs have become specifically
adapted to support a parasitic lifestyle, losing the more ancient
property of direct antimicrobial killing but acquiring the ability
to regulate immune responses in order to promote their
survival within the mammalian host. It is possible that HDM
immune modulation arose in trematodes following their
divergence from the chordate lineage (as acoelomates) and
their subsequent specialisation to an endoparasitic lifestyle,
distinct from the free-living acoelomate turbellarian flatworms
from which HDM homologues have yet to be identified
(unpublished observation).
The immune-modulatory properties of mammalian HDPs, and
in particular their ability to prevent excessive inflammatory
induced pathology associated with bacterial sepsis, has attracted
interest in exploiting these as anti-infectives. However, their
cytotoxicity, as also shown in the present study, has presented a
major drawback for their in vivo use. Accordingly, the absence of
cytotoxicity and retention of immune-modulatory activity ob-
served for the helminth-derived HDMs offer an opportunity to
design novel immunotherapeutics to combat microbial pathogens
and immune-related disorders.
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